Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of Optune plus maintenance temozolomide with pembrolizumab versus placebo in newly diagnosed glioblastoma
MOH_2025-02-25_013939Phase 3Recruiting
- Sponsor
- NovoCure
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing Optune + temozolomide + placebo with Optune + temozolomide + pembrolizumab (2 arms). Started Jan 2025; status: recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on MOH_2025-02-25_013939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-25_013939.